252,800
Modelled total
100% of estimated PLHIV
Surveillance Insights · Q2 2025
The Philippine HIV response, in numbers
Clear visualizations of the DOH Epidemiology Bureau's April – June 2025 surveillance report. Every figure here is reproduced exactly from the source — no edits, no estimates added.
95-95-95 cascade
National progress toward UNAIDS targets
As of 30 June 2025. Each step shows the share of the estimated 252,800 PLHIV.
144,192
1st 95 — 57%
57% of estimated PLHIV
95,556
2nd 95 — 66% of diagnosed
38% of estimated PLHIV
44,714
3rd 95 — 47% of on-ART
18% of estimated PLHIV
Avg. new diagnoses / month
1,679
+16% vs. same period last year
Newly enrolled on ART
4,316
Median baseline CD4 202 cells/mm³
Newly reported deaths
161
April – June 2025
Cumulative cases since 1984
153,798
9,606 reported deaths
New diagnoses per month, average by year
A 64% increase since 2021 — the steepest rise to date in Q2 2025.
Mode of transmission, Q2 2025
96% of newly reported cases were acquired through sexual contact.
New diagnoses by age group, Q2 2025
78% of newly diagnosed cases were 15–34 years old.
Cumulative diagnosed cases by sex
January 1984 – June 2025 · n = 153,798
Male · 94%Female · 6%
Care cascade by key population
MSM make up the largest population on ART; PWID show the largest treatment gap.
MSM
Est. 194,3001st 95 — diagnosed62%
2nd 95 — on ART68%
3rd 95 — suppressed48%
Other Males
Est. 36,5001st 95 — diagnosed38%
2nd 95 — on ART50%
3rd 95 — suppressed47%
Other Females
Est. 18,0001st 95 — diagnosed43%
2nd 95 — on ART42%
3rd 95 — suppressed50%
PWID
Est. 2,8001st 95 — diagnosed84%
2nd 95 — on ART25%
3rd 95 — suppressed36%
Regional 95-95-95 cascade
Sort to surface gaps. Bars are proportional to the row's maximum on that metric.
| Region | Estimated | Diagnosed | 1st 95 | 2nd 95 | 3rd 95 |
|---|---|---|---|---|---|
| NCR | 73,700 | 46,695 | 63% | 62% | 50% |
| 4A | 43,800 | 24,455 | 56% | 66% | 49% |
| 3 | 30,000 | 14,942 | 50% | 68% | 52% |
| 7 | 19,200 | 10,614 | 55% | 56% | 38% |
| 11 | 14,600 | 8,199 | 56% | 64% | 41% |
| 6 | 11,500 | 5,763 | 50% | 78% | 61% |
| 1 | 7,900 | 4,076 | 52% | 67% | 49% |
| 12 | 7,700 | 4,172 | 54% | 71% | 25% |
| NIR | 7,100 | 3,516 | 50% | 72% | 60% |
| 10 | 6,900 | 3,870 | 56% | 58% | 21% |
| 5 | 6,100 | 3,228 | 53% | 68% | 56% |
| 2 | 4,800 | 2,521 | 53% | 75% | 59% |
| 8 | 4,500 | 2,534 | 56% | 59% | 36% |
| 4B | 4,200 | 2,517 | 60% | 65% | 38% |
| 9 | 4,200 | 2,402 | 57% | 63% | 30% |
| CARAGA | 3,300 | 1,926 | 58% | 63% | 42% |
| CAR | 2,300 | 1,286 | 56% | 72% | 61% |
| BARMM | 900 | 565 | 63% | 56% | 33% |
Source: Department of Health · Epidemiology Bureau — HIV & AIDS Surveillance of the Philippines, April – June 2025. Figures reproduced verbatim from the published report. This page is an independent visualization and is not affiliated with the DOH.